Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-25

Study Completion Date

2019-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Laser therapy is increasingly showing promising results in dental field including oral ulcers.This trial will assess the usefulness of Diode Laser compared to corticosteroid on oral ulcers of patients diagnosed with Behcet's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.

NCT06971172

Pemphigus Vulgaris

NOT_YET_RECRUITING NA

Erbium-YAG Laser Versus Platelet Rich Plasma in the Treatment of Atrophic Acne Scars

NCT03933033

Acne Vulgaris Scars

COMPLETED NA

Impact of Tripolar Radiofrequency on Acne Scar

NCT06492356

Acne Scars - Mixed Atrophic and Hypertrophic Scar Radiofrequency

COMPLETED NA

577-nm Diode Laser in the Treatment of Non -Inflammatory Acne

NCT06909344

Acne

RECRUITING NA

Laser Therapy for Perioral Dermatitis

NCT03779295

Perioral Dermatitis

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The enrolled patients will be divided randomly into two groups.one group will receive Diode Laser (power:100 milli Watt,wavelength:980 mmm, delivery system:biostimulation probe) and other group will receive topical corticosteroids(Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermaphor) four times daily.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Behcet Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1:1

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Investigators

Double - blinded trial:

Outcome assessor (CS) and Statistician. Participants couldn't be blinded because of the difference in the nature of interventions method of application.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Triamcinolone acetonide

Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.

Group Type ACTIVE_COMPARATOR

Triamcinolone Acetonide

Intervention Type DRUG

0.1 \&5gm paste 4 times/day

Diode laser

Diode laser 980 nm \& 100mWatt.

Group Type EXPERIMENTAL

Diode laser 980nm&100 mWatt

Intervention Type RADIATION

Diode laser 980 nm \&100 milli Watt.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diode laser 980nm&100 mWatt

Diode laser 980 nm \&100 milli Watt.

Intervention Type RADIATION

Triamcinolone Acetonide

0.1 \&5gm paste 4 times/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Low level laser Biostimulation Soft laser Topical corticosteroid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with Behcet's Disease according to International Criteria for BD.
* patients with active oral ulcers.
* patients free from any visible oral lesions other than the oral ulcers of BD.
* patients who agreed to take the supplied interventions.
* patients who will agree to participate in the study.
* patients who will accept to sign the informed consent.

Exclusion Criteria

* patients not physically able to participate in survey or clinical oral examination.
* patients with organ or life-threatening disease.
* patients with history of a severe or chronic medical condition including tuberculosis, hepatitis and human immunodeficiency virus.
* patients under immunosuppressive drugs.
* patients with organ transplantation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No